Low Overall Survival in Women With De Novo Metastatic Breast Cancer: Does This Reflect Tumor Biology or a Lack of Access to Health Care?

Leonardo R. Soares, MD, PhD1; Ruffo Freitas-Junior, MD, PhD1,2; Maria P. Curado, MD, PhD3; Regis R. Paulinelli, MD, PhD1,2; Edesio Martins, BSc, PhD1; and José C. Oliveira, MD, PhD4

PURPOSE As a result of its epidemiologic and therapeutic aspects, metastatic breast cancer (MBC) is a highly relevant clinical condition. This study aimed to estimate overall survival (OS) in women with de novo MBC in a Brazilian population.

PATIENTS AND METHODS Patients were identified in the Goiânia population-based cancer registry between 1995 and 2011. All women with metastatic disease at diagnosis were included in the study. OS was analyzed at 5 and 10 years of follow-up. We used the Kaplan-Meier estimator and Cox regression for statistical analysis.

RESULTS Over the 16-year period covered by the study, 5,289 women were diagnosed with breast cancer in Goiânia. Of these, 277 women (5.2%) had MBC. OS rates at 5 and 10 years were 19.9% and 7.3%, respectively. The mean OS time of women treated in the public health system was 7.5 months shorter than in women who had private health care (19.7 vs 27.2 months, respectively). In the univariable analysis, the following factors were statistically significant for OS: T3/4 staging, histologic grade 3, progesterone receptor status, tumor phenotype, breast surgery, CNS metastasis at initial presentation, and surgery for resection of metastasis. In multivariable analysis, initial CNS metastasis (hazard ratio, 3.09; 95% CI, 1.16 to 8.19) and breast surgery (hazard ratio, 0.45; 95% CI, 0.25 to 0.78) remained independent prognostic factors.

CONCLUSION OS was lower than rates found in specialist centers in Brazil and in developed countries. Several intrinsic and extrinsic factors were significant in predicting OS. Despite the difference in the 5-year survival rate, the type of access to health care was not significant in the multivariable analysis of the entire period.

JCO Global Oncol 6:679-687. © 2020 by American Society of Clinical Oncology

INTRODUCTION Breast cancer is a public health issue of global scale. Two million new patients were estimated to be diagnosed worldwide in 2018,1 of whom 5% to 30% were expected to be diagnosed at metastatic stage.2-4 Over recent decades, screening programs in the United States have unexpectedly failed to reduce the percentage of women diagnosed at metastatic stage.5 Because breast cancer is a heterogeneous pathology with various patterns of tumor biology, it translates into individualized types of clinical behavior and therapeutic response.6,7

Metastatic breast cancer (MBC) is also a heterogeneous condition with a diverse clinical course.3,9,10 In recent years, increased knowledge on tumor biology, advances in the diagnosis of the disease, and access to new therapeutic agents have increased the overall survival (OS) of patients with MBC.10,11 Nevertheless, these advances have also uncovered new challenges regarding the management of the metastatic disease itself and of the adverse events caused by systemic treatment.12,13 Individuals with metastatic conditions are generally given a continuous regimen of palliative treatment, which results in a high demand on health care facilities as a result of the constant need for tests, prescription of medication, and hospitalization for clinical support.12,14,15

In low- and middle-income countries, there are additional problems, such as limited access to health care, with diagnosis often being made late and at more advanced stages, and the use of treatments below the already established standard.16,17 For example, in the Brazilian public health care system, which provides care to approximately 70% of the country’s population, trastuzumab became available for the treatment of metastatic HER2-positive breast cancer in 2017, almost 20 years after the US Food and Drug Administration approved the drug for use in the United States.18,19 With the subsequent introduction of the CDK4/6 inhibitors and other anti-HER2 therapies in high-income countries,10,20 this difference in oncologic outcomes may have increased even further.
Prognostic factors are ultimately associated with OS because they are indicators of various clinical outcomes involving the risk of recurrence or death. Identifying these factors is crucial for clinical follow-up and the specific treatment of patients with cancer. Currently, most of the data on MBC originate from retrospective, hospital-based studies or controlled trials involving specific populations and treatments. However, population-based studies have the advantage of enabling an epidemiologic analysis to be made of different populations, which may help in the development of specific public policies. Therefore, the objective of the current study was to estimate OS and identify the prognostic factors associated with MBC in a Brazilian population for the period from 1995 to 2011.

**PATIENTS AND METHODS**

An ecologic study of OS was conducted in patients with de novo MBC between January 1, 1995, and December 31, 2011. The patients were retrieved from a database at the Goiânia population-based cancer registry for the period from 1995 to 2011.

**Goiânia Population-Based Cancer Registry**

This cancer registry was created in 1986 and has registered all new patients with cancer diagnosed in the city of Goiânia uninterruptedly from its creation to the present day.

**Eligibility Criteria**

Women whose records were found to include the description “metastatic” or “unknown” under the heading “Extent of the Disease” were considered potentially eligible.

**Patients**

All women previously classified as having MBC at diagnosis were included in the study. This classification was determined by the patients’ clinical records, imaging tests, and/or histology results showing the presence of metastatic cancer (i.e., disease beyond the breast and axillae). We revised all the eligible patients by actively performing a search of the medical archives at the Goiás Association for the Combat of Cancer’s Araújo Jorge Hospital and at the Teaching Hospital of the Federal University of Goiás. Both hospitals are referral centers for cancer treatment in the city of Goiânia and active data collection sources for the population-based cancer registry. Patients with breast carcinoma in situ and patients without histologic confirmation were excluded from the study, as were patients for whom the only record of diagnosis was on the death certificate.

**Variables**

A questionnaire based on previous studies conducted with populations with metastatic cancer and the standardization used by the Goiânia population-based cancer registry were used for data collection. The following demographic variables were analyzed: age at diagnosis, age at menarche, family history of breast or ovarian cancer, and whether care was provided within the public or private health care system.

The site of the tumors and their morphologic classification were coded in accordance with the International Classification of Diseases for Oncology, third edition, encompassing the morphologic codes 8500/3, 8520/3, and 8521/3. Sarcomas (8800/3) and other morphologic types (anaplastic carcinoma and spindle cell types) were classified as other subtypes.

Histologic grade was classified as grade 1, 2, or 3 according to the Bloom-Richardson grading system. Locoregional staging was classified according to the TNM staging system, as defined in the eighth edition of the American Joint Committee on Cancer staging manual. The immunohistochemical expression of estrogen and progesterone receptors was considered positive or negative according to the report from each laboratory. HER2 expression was considered positive when the degree of positivity was expressed as 3 plus symbols (+++) or when confirmed by immunofluorescence. Tumor phenotype classification was determined in accordance with the recommendations of the 15th St Gallen International Breast Cancer Conference.

Data on the location of metastases were collected from the medical records at the 2 hospitals involved in the study. The site of metastatic lesions and the presence of associated clinical symptoms were evaluated, as well as whether
| Characteristic | No. of Patients | %   | Survival Rate (%) | Mean Survival Time (months) | 95% CI for Survival (months) | P  |
|---------------|-----------------|-----|-------------------|-----------------------------|------------------------------|----|
| Age at diagnosis, years (n = 277) |                |     |                   |                             |                              |    |
| ≤ 49          | 103             | 37.2| 16.6              | 25.4                        | 21.2 to 29.6                 | .4 |
| 50-59         | 75              | 27.1| 23.1              | 27.7                        | 22.4 to 33.0                 |    |
| ≥ 60          | 99              | 35.7| 16.1              | 23.4                        | 18.5 to 28.4                 |    |
| Presence of symptoms (n = 126) |                |     |                   |                             |                              | .1 |
| Yes           | 103             | 81.8| 8.9               | 20.4                        | 17.0 to 23.9                 |    |
| No            | 23              | 18.2| 19.7              | 27.2                        | 18.4 to 36.0                 |    |
| Histologic type (n = 136) |                |     |                   |                             |                              | .02|
| Carcinoma, not otherwise specified | 19          | 14.0| 0.0              | 16.2                        | 10.4 to 22.0                 |    |
| Ductal carcinoma | 107         | 78.6| 22.2              | 27.7                        | 23.5 to 31.9                 |    |
| Lobular carcinoma | 6          | 4.4 | 0.0               | 18.8                        | 5.1 to 32.4                  |    |
| Sarcoma and others | 4          | 3.0 | 0.0               | 15.0                        | 1.3 to 28.6                  |    |
| Histologic grade (n = 89) |                |     |                   |                             |                              | .03|
| 1             | 11              | 12.3| 51.9              | 37.3                        | 22.2 to 52.5                 |    |
| 2             | 51              | 57.3| 18.0              | 30.2                        | 24.8 to 35.6                 |    |
| 3             | 27              | 30.4| 8.0               | 21.8                        | 15.1 to 28.4                 |    |
| Estrogen receptor status (n = 79) |                |     |                   |                             |                              | .02|
| Positive      | 53              | 67.1| 26.4              | 33.5                        | 28.2 to 38.9                 |    |
| Negative      | 26              | 32.9| 5.1               | 24.7                        | 18.3 to 31.2                 |    |
| Progesterone receptor status (n = 76) |                |     |                   |                             |                              | <.01|
| Positive      | 42              | 55.3| 35.1              | 38.9                        | 33.2 to 44.6                 |    |
| Negative      | 34              | 44.7| 3.0               | 21.4                        | 16.2 to 26.6                 |    |
| c-erbB (n = 71) |                |     |                   |                             |                              | .4 |
| Positive      | 24              | 33.8| 11.7              | 29.1                        | 21.8 to 36.3                 |    |
| Negative      | 47              | 66.2| 24.1              | 31.8                        | 26.1 to 37.5                 |    |
| Tumor phenotype (n = 71) |                |     |                   |                             |                              | .02|
| Luminal       | 34              | 47.9| 33.0              | 36.9                        | 30.5 to 43.3                 |    |
| Luminal-HER2  | 16              | 22.5| 15.7              | 28.4                        | 17.6 to 39.2                 |    |
| HER2          | 8               | 11.3| 0.0               | 27.2                        | 19.1 to 35.3                 |    |
| Triple negative | 13          | 18.3| 7.7               | 20.2                        | 11.2 to 29.1                 |    |

(Continued on following page)
### TABLE 1. Clinical Characteristics and Overall Survival at 60 Months of Follow-Up in Patients With De Novo Metastatic Breast Cancer in the City of Goiânia (1995-2011) (Continued)

| Characteristic                  | No. of Patients | %     | Survival Rate (%) | Mean Survival Time (months) | 95% CI for Survival (months) | P   |
|---------------------------------|-----------------|-------|-------------------|----------------------------|-------------------------------|-----|
| **T stage (n = 129)**           |                 |       |                   |                            |                               |     |
| T0                              | 3               | 2.3   | 0.0               | 18.7                       | 4.5 to 32.9                   | .01 |
| T1                              | 12              | 9.3   | 41.7              | 38.1                       | 26.0 to 50.2                  |     |
| T2                              | 22              | 17.1  | 36.9              | 36.4                       | 27.6 to 45.2                  |     |
| T3                              | 25              | 19.4  | 12.0              | 21.1                       | 13.6 to 28.7                  |     |
| T4                              | 67              | 51.9  | 11.4              | 21.1                       | 16.4 to 25.9                  |     |
| **N stage (n = 123)**           |                 |       |                   |                            |                               | .5  |
| N0                              | 31              | 25.2  | 23.8              | 30.0                       | 22.3 to 37.6                  |     |
| N1                              | 40              | 32.5  | 22.2              | 23.1                       | 16.1 to 30.1                  |     |
| N2                              | 37              | 30.1  | 8.3               | 23.4                       | 17.5 to 29.4                  |     |
| N3                              | 15              | 12.2  | 13.3              | 21.8                       | 12.4 to 31.3                  |     |
| **Type of health care (n = 128)**|                 |       |                   |                            |                               | .04 |
| Public                          | 90              | 70.3  | 6.9               | 19.7                       | 16.2 to 23.3                  |     |
| Private                         | 38              | 29.7  | 22.4              | 27.2                       | 20.2 to 34.1                  |     |
| **Site of metastases (n = 129)**|                 |       |                   |                            |                               | .02 |
| Bone                            | 36              | 27.9  | 20.9              | 27.2                       | 20.1 to 34.2                  |     |
| Visceral                        | 41              | 31.8  | 10.4              | 22.0                       | 16.4 to 27.7                  |     |
| Visceral and bone               | 24              | 18.6  | 9.2               | 20.4                       | 13.1 to 27.7                  |     |
| CNS                             | 11              | 8.5   | 0.0               | 9.8                        | 4.7 to 15.0                   |     |
| Skin, subcutaneous cell tissue, or distant lymph nodes | 17 | 13.2 | 5.9 | 20.7 | 12.9 to 28.4 |     |
| **Surgery to resect breast tumor (n = 123)** | | | | | | < .01 |
| Yes                             | 50              | 40.6  | 21.0              | 31.7                       | 25.9 to 37.4                  |     |
| No                              | 73              | 59.4  | 5.7               | 16.0                       | 12.5 to 19.5                  |     |
| **Metastasis extirpation (n = 108)** | | | | | | .08 |
| Yes                             | 10              | 9.4   | 30.0              | 33.5                       | 18.7 to 48.4                  |     |
| No                              | 98              | 90.8  | 9.8               | 20.9                       | 17.7 to 24.2                  |     |

Abbreviation: HER2, human epidermal growth factor receptor 2.

Numbers of individuals with data for each variable are in parentheses.

Log-rank test.
aspiration and/or biopsy of the lesions had been performed. With respect to treatment, data were collected on the type of surgery performed for the primary tumor and/or metastasis and the use of systemic treatments.

**Survival**

For the survival analysis, the cutoff date for the duration of follow-up or active search for the women was December 31, 2018. Initially, the data available in the registry database and/or medical records were retrieved. To complete the data set with information on patients’ vital status, a search was made of the Goiás mortality database, the electoral roll, and the Municipal Social Services Department.

**Data Analysis**

OS was divided into analyses conducted at 5 and 10 years of follow-up and over the entire period. Time of follow-up was calculated from the date of diagnosis until the occurrence of the event of interest (death) or until censure (ie, women who remained alive at the end of the follow-up time were censored).

The database was constructed and the statistical analysis conducted using the SPSS software package for Windows, version 22.0 (IBM Corporation, Armonk, NY) and MedCalc for Windows, version 18.11 (MedCalc Software, Ostend, Belgium). The qualitative variables were described using frequency distributions and percentages. The distribution of survival was calculated using the Kaplan-Meier estimator and compared between the groups using the log-rank test, with 95% CIs. Cox regression analysis was used for the univariable and multivariable analysis. First, all the potential prognostic variables were tested, each by using the univariable Cox regression model. The prognostic variables with a significance level of \( P < .05 \) were considered as candidates for the multivariable analysis. In addition, interaction between the variables was tested, and none returned significant values. \( P < .05 \) was considered statistically significant.

**Ethical Issues**

The internal review board of the Association for the Combat of Cancer’s Araujo Jorge Hospital approved the study protocol under reference No. CAAE 61987716.0.0000.0031. All the recommendations of good clinical practice outlined in the Brazilian National Health Council’s resolution 466/2012 and in the Declaration of Helsinki were followed.

**RESULTS**

Over the 16-year period analyzed, 5,289 breast cancers were diagnosed in residents of the city of Goiânia, Brazil. Of these, 277 cancers (5.2%) were identified as de novo MBC. Access to the patient’s medical records was obtained in 156 of these patients, the majority of whom (70.3%) were treated in the public health care system.

The mean age of the women with MBC included in this study was 54.7 years (standard deviation, 14.5 years). Eighty-eight patients (68.2%) had only one metastatic site (Fig 1). The mean survival time was 37.2 months (95% CI, 31.5 to 42.2 months), and the median survival time was 20.0 months (95% CI, 16.3 to 23.7 months). The mean OS of women treated in the public health system was 7.5 months shorter than in private health care users (19.7 vs 27.2 months, respectively; Table 1).

**DISCUSSION**

To our knowledge, this is the first population-based study dealing with MBC to be conducted in Brazil. In the United States, approximately 6% of women are diagnosed with MBC, a figure that is similar to the percentage of 5.2% found in this series. In the current study, the OS rate was 19.9% at 5 years and 7.3% at 10 years in a population of women with MBC in the city of Goiânia. In women with...
| Factor                                      | HR    | 95% CI       | No. of Patients (%) | Wald | P     |
|--------------------------------------------|-------|--------------|---------------------|------|-------|
| Age, years                                 |       |              |                     |      |       |
| < 50                                       | 1     | —            | 103 (37.18)         |      | —     |
| 50-59                                      | 0.94  | 0.69 to 1.29 | 75 (27.08)          | 0.15 | .70   |
| ≥ 60                                       | 1.24  | 0.92 to 1.67 | 99 (35.74)          | 2.02 | .15   |
| Age > 60 years                              | 1.27  | 0.98 to 1.66 | 99 (35.74)          | 3.16 | .07   |
| Menarche > 12 years old                    | 1.04  | 0.53 to 2.03 | 32 (69.57)          | 0.011| .91   |
| First-degree family history (breast or ovary) | 1.62  | 0.85 to 3.09 | 12 (18.18)          | 2.11 | .14   |
| Ductal histology                           | 0.60  | 0.31 to 1.14 | 126 (92.65)         | 2.42 | .12   |
| Grade                                      |       |              |                     |      |       |
| 1                                          | 1     | —            | 11 (12.36)          |      | —     |
| 2                                          | 1.43  | 0.72 to 2.85 | 51 (57.30)          | 1.06 | .30   |
| 3                                          | 2.29  | 1.08 to 4.89 | 27 (30.34)          | 4.61 | .03   |
| Grade 3                                    | 1.70  | 1.05 to 2.73 | 27 (30.34)          | 4.74 | .02   |
| T3/4                                       | 1.80  | 1.21 to 2.67 | 92 (71.32)          | 8.58 | < .01 |
| Node positive                              | 1.39  | 0.92 to 2.11 | 89 (74.80)          | 2.38 | .12   |
| ER positive                                | 0.64  | 0.40 to 1.04 | 53 (37.09)          | 3.23 | .07   |
| PR positive                                | 0.43  | 0.26 to 0.68 | 42 (55.26)          | 12.51| < .01 |
| HER2 positive                              | 1.31  | 0.79 to 2.17 | 24 (33.80)          | 1.11 | .29   |
| Subtype                                    |       |              |                     |      |       |
| Luminal                                    | 1     | —            | 34 (47.89)          |      | —     |
| Luminal/HER                                | 1.42  | 0.78 to 2.60 | 16 (22.54)          | 1.28 | .25   |
| HER positive                               | 1.86  | 0.84 to 4.12 | 8 (11.27)           | 2.33 | .12   |
| TN                                         | 2.04  | 1.06 to 3.92 | 13 (18.31)          | 4.58 | .03   |
| Luminal                                    | 0.60  | 0.40 to 1.00 | 50 (70.42)          | 3.82 | .05   |
| Multiple metastatic sites                  | 1.36  | 0.92 to 1.99 | 41 (31.78)          | 2.41 | .12   |
| Primary metastatic site                    |       |              |                     |      |       |
| Bone only                                  | 1     | —            | 36 (27.91)          |      | —     |
| Visceral only                              | 1.24  | 0.78 to 1.97 | 41 (31.78)          | 0.87 | .35   |
| Visceral and bone                          | 1.45  | 0.85 to 2.46 | 24 (18.60)          | 1.89 | .16   |
| Skin, subcutaneous tissue, or lymph nodes  | 1.36  | 0.76 to 2.46 | 17 (13.18)          | 1.07 | .30   |
| CNS                                        | 2.75  | 1.32 to 5.69 | 11 (8.53)           | 7.40 | < .01 |
| Initial CNS metastasis                     | 2.24  | 1.16 to 4.35 | 11 (8.53)           | 5.69 | .01   |
| Public funding                             | 1.30  | 0.88 to 1.92 | 90 (70.31)          | 1.78 | .18   |
| No breast surgery                          | 2.22  | 1.51 to 3.27 | 73 (59.35)          | 16.26| < .01 |
| Surgery of the metastasis                  |       |              |                     |      |       |
| Excisional biopsy                          | 1     | —            | 10 (7.81)           |      | —     |
| Incisional biopsy                          | 1.69  | 0.78 to 3.66 | 20 (15.63)          | 1.77 | .18   |
| No Surgery                                 | 2.02  | 1.03 to 3.97 | 98 (76.56)          | 4.21 | .04   |
| Metastasis extirpation                     | 0.51  | 0.26 to 1.00 | 10 (7.81)           | 3.86 | .05   |
| Symptomatic metastasis                     | 1.45  | 0.90 to 2.34 | 103 (81.75)         | 2.37 | .12   |

Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor; RT, radiotherapy; TN, triple negative.

*Cox regression.
In the present series, several factors proved significant that affect OS. Breast cancer, controversies remain regarding the factors is different. The ever, these are groups of patients in whom biologic behavior have been well established24; however, in women with metastatic breast cancer, such as histologic grade, tumor size, and axillary status have already been well established24; however, in women with metastatic breast cancer, controversies remain regarding the factors that affect OS.

In the present series, several factors proved significantly prognostic of OS. Factors related to the primary tumor such as histologic grade, as well as factors related to metastatic progression such as the initial site of metastases, significantly predicted OS. Other studies conducted around the world have reported several possible prognostic factors in MBC, such as, for example, patient age and the number of organs involved.9,23,26,33 However, the majority of those studies analyzed patients who had metastases at diagnosis and patients who went on to develop metastasis after a disease-free interval as a single mixed sample.26 However, these are groups of patients in whom biologic behavior is different. The findings of this population-based study, which included only women with MBC detected at diagnosis, contribute to a better characterization of the prognostic factors involved in patients with advanced disease at diagnosis.

Performing breast surgery in women with metastatic disease remains controversial and is usually reserved for selected patients.12,23,34,35 At the time this study was conducted, scientific evidence was limited to retrospective, noncontrolled studies that showed greater OS rates in patients who underwent breast surgery.34 Therefore, the finding of better survival rates in the women who underwent local treatment should be interpreted with caution, bearing in mind that a selection bias could have led the patients with a better prognosis to receive breast surgery and the patients with more extensive disease to receive systemic treatment alone. However, the poor survival in the population with CNS metastasis is probably a result of therapeutic limitations in these patients, whose blood-brain barrier limits the efficacy of systemic treatment.36

In recent years, increased knowledge regarding tumor biology has led to the development of new therapeutic agents that have contributed to increasing survival in patients with MBC.10,11 For example, women with MBC and hormone receptor–positive or HER2-positive tumors seem to have similar oncologic outcomes when treated appropriately. However, OS and progression-free survival are poorer in women with triple-negative tumors.1,23,37 Regrettably, the small number of patients in the present series who received anti-HER2 treatment (n = 3; 18.7%) points to socioeconomic constraints that restrict access to treatment. Conversely, the underutilization of endocrine therapy as first-line treatment of MBC may reflect inappropriate therapeutic conduct according to current recommendations and the standards in force during the period analyzed.12,13,20

The majority of the women included in the current study were patients in the public health care system, with limited access to early diagnosis and to the most effective forms of treatment.13,19 Therefore, 5- and 10-year OS rates were low. A study conducted by the Brazilian Breast Cancer Research Group found that the type of health care system affected OS, with rates being lower for patients in the public health care system compared with those receiving care in the private sector, particularly in patients with stage III or IV disease at diagnosis.38 In São Paulo, Brazil, a hospital-based study included 205 patients with MBC who had received similar oncologic treatment irrespective of their access to either public or private health care. In that series, 5-year OS was 20.7% between 2000 and 2004, 33.3% between 2005 and 2009, and 40.8% between 2010 and 2012.39

OS rates in women with MBC vary in the literature. A collaborative study conducted in 18 comprehensive cancer centers in France reported an OS of 37.2 months. After 5 years of follow-up, OS was practically twice that found in the current study.26 In randomized clinical trials conducted in specific populations, this difference is even greater. For example, in the Clinical Evaluation of Pertuzumab and Trastuzumab Trial (CLEOPATRA), the median OS time was 56.5 months in women with HER2-positive tumors who received pertuzumab in addition to the standard first-line treatment of MBC.40 Nevertheless, the majority of those studies failed to describe specific results for the women with de novo MBC and also do not reflect what is practiced in the public health care systems of most low- and middle-income countries.

The current study has some limitations that are inherent to retrospective studies, such as missing data in the medical records and even in the cancer registry database. Tumor phenotypes were established by immunohistochemistry, and no central review was conducted of the pathology reports, which could have affected the interpretation of these data.41 However, the fact that the medical records identified were verified manually added greater robustness to the study and provided data on variables that are not systematically collected by the cancer registry. Finally, the

| Factor                  | HR    | 95% CI   | Wald | P       |
|-------------------------|-------|----------|------|---------|
| Age > 60 years          | 1.32  | 0.70 to 2.50 | 0.74 | .39     |
| Grade 3                 | 1.15  | 0.70 to 1.92 | 0.30 | .58     |
| T3/4                    | 1.05  | 0.60 to 1.83 | 0.03 | .87     |
| Initial CNS metastasis  | 3.09  | 1.16 to 8.19 | 5.13 | .02     |
| Metastasis extirpation   | 0.63  | 0.28 to 1.45 | 1.16 | .28     |
| Breast surgery          | 0.45  | 0.25 to 0.78 | 7.86 | < .01   |

Abbreviation: HR, hazard ratio.
*Cox regression.
relevance of population-based registries in the context of MBC should be emphasized, considering that it is a heterogeneous population and with several particularities. Thus, collaborative records for patients with metastatic disease should be advocated, allowing the collection of de novo and recurrent case information.

**AFFILIATIONS**
1. Breast Program, Teaching Hospital, Federal University of Goiás, Goiânia, Goiás, Brazil
2. Hospital Araújo Jorge, Association for the Combat of Cancer in Goiás, Goiânia, Goiás, Brazil
3. A.C. Camargo Cancer Center, Fundação Antônio Prudente, São Paulo, São Paulo, Brazil
4. Goiânia Population-Based Cancer Registry, Association for the Combat of Cancer in Goiás, Goiânia, Goiás, Brazil

**CORRESPONDING AUTHOR**
Ruffo Freitas-Junior, MD, PhD, Centro Avançado de Diagnóstico da Mama, 1° Avenida, s/n, Setor Universitário, 74605-050, Goiânia, Goiás, Brazil; e-mail: ruffojr@terra.com.br.

**PRIOR PRESENTATION**
Presented in part at the Brazilian Breast Cancer Symposium, Goiás, Brazil, May 16-18, 2019; and in part at the 2019 São Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2019.

**AUTHOR CONTRIBUTIONS**
Conception and design: Leonardo R. Soares, Ruffo Freitas-Junior, Maria P. Curado, José C. Oliveira
Administrative support: Ruffo Freitas-Junior, Edesio Martins
 Provision of study material or patients: Ruffo Freitas-Junior, José C. Oliveira
Collection and assembly of data: Ruffo Freitas-Junior, Regis R. Paulinelli
Data analysis and interpretation: Leonardo R. Soares, Ruffo Freitas-Junior, Regis R. Paulinelli, Edesio Martins
Manuscript writing: All authors

**REFERENCES**
1. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018
2. Lee T, Isaacs C: Treatment of primary breast tumors in de novo metastatic breast cancer. Clin Adv Hematol Oncol 12:820e7, 2014
3. Cardoso F, Spence D, Mertz S, et al: Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). Breast 39:131-138, 2018
4. Nunes RD, Martins E, Freitas-Junior R, et al: Descriptive study of breast cancer cases in Goiânia between 1989 and 2003. Rev Col Bras Cir 38:212-216, 2011
5. National Cancer Institute Surveillance, Epidemiology, and End Results Program: Cancer Stat Facts: Female breast cancer. https://seer.cancer.gov/statfacts/html/breast.html
6. Ping Z, Xia Y, Shen T, et al: A microscopic landscape of the invasive breast cancer genome. Sci Rep 6:27545, 2016
7. Dowsett M, Cuzick J, Ingle J, et al: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518, 2010
8. Sparano JA, Gray RJ, Makower DF, et al: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111-121, 2018
9. Ren Z, Li Y, Hameed O, et al: Prognostic factors in patients with metastatic breast cancer at the time of diagnosis. Pathol Res Pract 210:301-306, 2014
10. De Placido S, Giuliano M, Schettini F, et al: Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast 38:86-91, 2018
11. Turner NC, Slamon DJ, Ro J, et al: Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379:1926-1936, 2018
12. National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Fort Washington, PA, NCCN, 2019. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
13. Cardoso F, Senkus E, Costa A, et al: 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol 29:1634-1657, 2018
14. Dvořák E, Gout-Zwart J, Ejssen EL, et al: Comparative cost-effectiveness of drugs in early versus late stages of cancer: Review of the literature and a case study in breast cancer. PLoS One 11:e0146551, 2016
15. Figueiredo FWDS, Almeida TCD, Cardial DT, et al: The role of health policy in the burden of breast cancer in Brazil. BMC Womens Health 17:121, 2017

OS was low in this population and lower than rates found in specialist centers in Brazil and in developed countries. Several intrinsic and extrinsic factors were significant in predicting OS. Despite the difference in the 5-year survival rate, the type of access to health care was not significant in the multivariable analysis of the entire period.

**ACKNOWLEDGMENT**
We thank Libbs Farmacêutica for supporting this publication (Request No. 4400072920).
16. Simon SD, Bines J, Werutsky G, et al: Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study. Breast 44:113-119, 2019

17. Castro MC, Massuda A, Almeida G, et al: Brazil's unified health system: The first 30 years and prospects for the future. Lancet 394:345-356, 2019

18. Ministério da Saúde, Brasil, Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Diário Oficial da União. Brasilia, DF: Ago 03, 2017. Portaria no 29, de 02 de agosto de 2017. Seção 1, pagina 114

19. Barrios CH, Reinert T, Werutsky G: Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab. Ecamermedicals 13:898, 2019

20. Kish JK, Ward MA, Garofalo D, et al: Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res 20:37, 2018

21. Renna Junior NL, Silva GAE: Late-stage diagnosis of breast cancer in Brazil: Analysis of data from hospital-based cancer registries (2000-2012). Rev Bras Ginecol Obstet 40:127-136, 2018

22. Barrios CH, Uema D, Cronenberger E, et al: Real world data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study. Cancer Res 77, 2017 (suppl 4; abstr P6-16-04)

23. Pons-Tostivint E, Kirova Y, Lusque A, et al: Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: A propensity score-matched analysis. Ann Surg Oncol 26:356-365, 2019

24. Freitas R, Nunes RD, Martins E, et al: Prognostic factors and overall survival of breast cancer in the city of Goiânia, Brazil: A population-based study. Rev Col Bras Cir 44:435-443, 2017

25. Moura L, Cunado MP, Simões EJ, et al: [Evaluation of the population based cancer registry of the Municipality of Goiânia, Goiás State, Brazil.] Epidemiol Serv Saude 16:7-17, 2006

26. Gobbini E, Ezzaifihi M, Dieras V, et al: Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer 96:17-24, 2018

27. Fritz AG, Percy C, Jack A (eds): International Classification of Diseases for Oncology (ed 3). Geneva, Switzerland, World Health Organization, 2000

28. Fritz AG, Percy C, Jack A (eds): International Classification of Diseases for Oncology (ed 3, revision 1). Geneva, Switzerland, World Health Organization, 2013

29. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359-377, 1957

30. Amin MB, Edge S, Greene F, et al (eds): Breast, in AJCC Cancer Staging Manual (ed 8). New York, NY, Springer International Publishing, 2016

31. Giuliano AE, Edge SB, Hortobagyi GN: Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Ann Surg Oncol 25:1783-1785, 2018

32. Curigliano G, Burstein HJ, P. Winer EP, et al: De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28:1700-1712, 2017

33. Rogetto B. Houezé de la Fuente A, Duhamel A, et al: Thirty-year trends of survival and time-varying effects of prognostic factors in patients with metastatic breast cancer: A single institution experience. Clin Breast Cancer 18:246-253, 2018

34. Xiao W, Zou Y, Zheng S, et al: Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol 44:1504-1512, 2018

35. Tosello G, Torloni MR, Mota BS, et al: Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev 3:CD011276, 2018

36. Znidaric T, Gugic J, Marinco T, et al: Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes. Breast J 25:1117-1125, 2019

37. Bonotto M, Gerratana L, Poletto E, et al: Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19:608-615, 2014

38. Liedke PER, Finkelstein DM, Szymonifka J, et al: Outcomes of breast cancer in Brazil related to health care coverage: A retrospective cohort study. Cancer Epidemiol Biomarkers Prev 23:126-133, 2014

39. Makdissi FB, Leite FPM, Peres SV, et al: Breast cancer survival in a Brazilian cancer center: A cohort study of 5,095 patients. Mastology 29:37-46, 2019

40. Swain SM, Baselga J, Kim SB, et al: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724-734, 2015

41. Wuerstlein R, Kates R, Gluz O, et al: Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study. Breast Cancer Res Treat 175:389-399, 2019